Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced its participation in several upcoming investor and scientific conferences. The company will present at the International mRNA Health Conference on November 10, 2020, at 1:40 p.m. ET, and at the Stifel Healthcare Conference on November 17, 2020, at 3:20 p.m. ET. Additionally, Arcturus will engage in a fireside chat at the Piper Sandler Healthcare Conference on November 23, 2020, at 10:00 a.m. ET. The company focuses on mRNA medicines and vaccines for infectious diseases and rare diseases.

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually:

•		International mRNA Health Conference
		Presentation
		Date: Tuesday, November 10, 2020
		Time: 1:40 p.m. ET
•		Stifel Healthcare Conference
		Presentation
		Date: Tuesday, November 17, 2020
		Time: 3:20 p.m. ET
•		Piper Sandler Healthcare Conference
		Fireside Chat
		Date: Monday, November 23, 2020
		Time: 10:00 a.m. ET

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (200 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.